Skip to content

Study · Randomized controlled trial · n = 17 · 2021

7 results

Neurochemical evidence for differential effects of acute and repeated oxytocin administration.

Benner S, Aoki Y, Watanabe T, Endo N, Abe O, Kuroda M, Kuwabara H, Kawakubo Y, Takao H, Kunimatsu A, Kasai K, Bito H, Kakeyama M, Yamasue H

Molecular psychiatry27 Sept 2018Cited by 25 (Europe PMC)

PMID30262887 (opens in a new tab)DOI10.1038/s41380-018-0249-4 (opens in a new tab)PepBankPUB-30262887
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In men with autism spectrum disorder, 6 weeks of intranasal oxytocin decreased medial prefrontal N-acetylaspartate versus placebo (p = 0.043).

    In plain wordsIn men with autism, 6 weeks of oxytocin lowered a brain chemical marker (NAA) in the front of the brain, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseMedial prefrontal NAA after repeated oxytocin
    Study

    n = 17

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
    1 context sentence
    Summary · context
    Human study analyzed medial prefrontal metabolite levels by using 1H-magnetic resonance spectroscopy, a secondary outcome in our randomized, double-blind, placebo-controlled crossover trial of 6 weeks intranasal administrations of oxytocin (48 IU/day) and placebo within-subject design in…
  2. 02HumanRandomized controlled trialMechanism

    In men with autism spectrum disorder, 6 weeks of intranasal oxytocin decreased medial prefrontal glutamate-glutamine levels versus placebo (p = 0.001).

    In plain wordsIn men with autism, 6 weeks of oxytocin lowered glutamate-glutamine levels in the front of the brain, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseMedial prefrontal glutamate-glutamine (Glx) after repeated oxytocin
    Study

    n = 17

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Source sentences

    Summary
    As the results, repeated administration of oxytocin significantly decreased the medial prefrontal N-acetylaspartate (NAA; p = 0.043) and glutamate-glutamine levels (Glx; p = 0.001), unlike the acute oxytocin.
    1 context sentence
    Summary · context
    Human study analyzed medial prefrontal metabolite levels by using 1H-magnetic resonance spectroscopy, a secondary outcome in our randomized, double-blind, placebo-controlled crossover trial of 6 weeks intranasal administrations of oxytocin (48 IU/day) and placebo within-subject design in…
  3. 03HumanRandomized controlled trialMechanism

    In men with autism spectrum disorder, the oxytocin-induced NAA decrease was inversely associated with oxytocin-induced improvement of medial prefrontal fMRI activity (r = 0.680, p = 0.004).

    In plain wordsIn men with autism, a bigger oxytocin-linked drop in the brain marker NAA went with a bigger gain in front-brain activity during a social task.

    Peptide
    Oxytocin
    Outcome
    Not applicableAssociation of NAA decrease with fMRI improvement
    Study

    n = 17

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    r
    0.68
    NAA, medial prefrontal
    p
    0.004
    NAA association

    Source sentences

    Summary
    The decreases were inversely and specifically associated (r = 0.680, p = 0.004 for NAA; r = 0.491, p = 0.053 for Glx) with oxytocin-induced improvements of medial prefrontal functional MRI activity during a social judgment task not with changes during placebo administrations.
    1 context sentence
    Summary · context
    Human study analyzed medial prefrontal metabolite levels by using 1H-magnetic resonance spectroscopy, a secondary outcome in our randomized, double-blind, placebo-controlled crossover trial of 6 weeks intranasal administrations of oxytocin (48 IU/day) and placebo within-subject design in…
  4. 04HumanRandomized controlled trialMechanism

    In men with autism spectrum disorder, the oxytocin-induced Glx decrease showed an inverse association with improvement of medial prefrontal fMRI activity that was not statistically significant (r = 0.491, p = 0.053).

    In plain wordsIn men with autism, the oxytocin-linked drop in glutamate-glutamine showed a weaker link to front-brain gains during a social task.

    Peptide
    Oxytocin
    Outcome
    Not applicableAssociation of Glx decrease with fMRI improvement
    Study

    n = 17

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    48 IU/day · intranasal · 6 weeksAs given in this study (human).

    Measurements

    r
    0.491
    Glx, medial prefrontal
    p
    0.053
    Glx association

    Source sentences

    Summary
    The decreases were inversely and specifically associated (r = 0.680, p = 0.004 for NAA; r = 0.491, p = 0.053 for Glx) with oxytocin-induced improvements of medial prefrontal functional MRI activity during a social judgment task not with changes during placebo administrations.
    1 context sentence
    Summary · context
    Human study analyzed medial prefrontal metabolite levels by using 1H-magnetic resonance spectroscopy, a secondary outcome in our randomized, double-blind, placebo-controlled crossover trial of 6 weeks intranasal administrations of oxytocin (48 IU/day) and placebo within-subject design in…
  5. 05AnimalAnimal study (in vivo)Mechanism

    In adult male mice, 14 days of intraperitoneal oxytocin reduced medial frontal transcript expression of NMDA receptor type 2B versus saline (p = 0.018).

    In plain wordsIn mice, 14 days of oxytocin lowered the activity of the gene for a glutamate receptor in the front of the brain, compared with saline.

    Peptide
    Oxytocin
    Outcome
    DecreaseMedial frontal NMDA receptor 2B transcript after repeated oxytocin
    Study

    mousen = 16

    adult male C57BL/6J mice
    Comparator
    Saline
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    200 ng/100 μL/mouse/day · intraperitoneal · 14 consecutive daysAs given in this study (mouse).

    Source sentences

    Summary
    In wild-type mice, we found that repeated oxytocin administration reduced medial frontal transcript expression of N-methyl-D-aspartate receptor type 2B (p = 0.018), unlike the acute oxytocin, which instead changed the transcript expression associated with oxytocin (p = 0.0004) and neural activity (p = 0.0002).
    1 context sentence
    Summary · context
    Medial prefrontal transcript expression levels were analyzed in adult male C57BL/6J mice after intraperitoneal injection of oxytocin or saline either once (200 ng/100 μL/mouse, n = 12) or for 14 consecutive days (200 ng/100 μL/mouse/day, n = 16).
  6. 06AnimalAnimal study (in vivo)Mechanism

    In adult male mice, a single intraperitoneal oxytocin dose changed the medial frontal transcript expression associated with oxytocin versus saline (p = 0.0004).

    In plain wordsIn mice, one oxytocin injection changed the activity of oxytocin-linked genes in the front of the brain, compared with saline.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedMedial frontal oxytocin-associated transcripts after acute oxytocin
    Study

    mousen = 12

    adult male C57BL/6J mice
    Comparator
    Saline
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    200 ng/100 μL/mouse · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    which instead changed the transcript expression associated with oxytocin (p = 0.0004) and neural activity (p = 0.0002).
    1 context sentence
    Summary · context
    Medial prefrontal transcript expression levels were analyzed in adult male C57BL/6J mice after intraperitoneal injection of oxytocin or saline either once (200 ng/100 μL/mouse, n = 12) or for 14 consecutive days (200 ng/100 μL/mouse/day, n = 16).
  7. 07AnimalAnimal study (in vivo)Mechanism

    In adult male mice, a single intraperitoneal oxytocin dose changed medial frontal transcript expression associated with neural activity versus saline (p = 0.0002).

    In plain wordsIn mice, one oxytocin injection changed the activity of genes linked to neural activity in the front of the brain, compared with saline.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedMedial frontal neural activity transcripts after acute oxytocin
    Study

    mousen = 12

    adult male C57BL/6J mice
    Comparator
    Saline
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    200 ng/100 μL/mouse · intraperitoneal · single injectionAs given in this study (mouse).

    Source sentences

    Summary
    which instead changed the transcript expression associated with oxytocin (p = 0.0004) and neural activity (p = 0.0002).
    1 context sentence
    Summary · context
    Medial prefrontal transcript expression levels were analyzed in adult male C57BL/6J mice after intraperitoneal injection of oxytocin or saline either once (200 ng/100 μL/mouse, n = 12) or for 14 consecutive days (200 ng/100 μL/mouse/day, n = 16).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.